PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10418968-11	1999	Furafylline, sulfaphenazole, quinidine, and ketoconazole were found to be specific inhibitors of CYP1A2, CYP2C9, CYP2D6, and CYP3A4, respectively.	Ketoconazole	44-56	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	97-103	
9384460-6	1997	Formation of DCLZ was inhibited by fluvoxamine (53 +/- 28% at 10 microM), triacetyloleandomycin (33 +/- 15% at 10 microM), and ketoconazole (51 +/- 28% at 2 microM) and by antibodies against CYP1A2 and CYP3A4.	Ketoconazole	127-139	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	191-197	
10078840-6	1999	Furafylline, sulphaphenazole, omeprazole, quinidine and ketoconazole were identified as specific markers for the respective CYP1A2 (IC50 = 6 microM), CYP2C9 (0.7 microM), CYP2C19 (6 microM), CYP2D6 (0.02 microM) and CYP3A4 (0.2 microM) inhibition screens.	Ketoconazole	56-68	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	124-130	
9531525-7	1998	Ketoconazole (5 microM), a selective CYP3A inhibitor, produced up to 75% inhibition, whereas other CYP-specific inhibitors, i.e. quinidine (CYP2D6), 7,8-benzoflavone (CYP1A2), and sulfaphenazole (CYP2C9), showed no significant effects.	Ketoconazole	0-12	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	167-173	
9925971-5	1999	For formation of M2, both a rabbit CYP3A polyclonal antibody (110 microliter/mg microsomal protein) and ketoconazole (2 micromol/l), a CYP3A inhibitor, showed about 50% inhibitory effects; other specific inhibitors of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 showed no significant effects.	Ketoconazole	104-116	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	218-224	
25159194-6	2015	Co-administration of pomalidomide with fluvoxamine (CYP1A2 inhibitor) in the presence of ketoconazole approximately doubled pomalidomide exposure.	Ketoconazole	89-101	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	52-58	
8591723-4	1995	Studies with human hepatic microsomes and the specific inhibitors furafylene, quinidine, and ketoconazole confirmed the role of CYP1A2 and CYP2D6 and also demonstrated the involvement of the CYP3A subfamily.	Ketoconazole	93-105	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	128-134	
29155491-6	2018	The CYP3A4-selective inhibitor ketoconazole (2 muM) impaired CLZ N-oxide formation in all 14 of the livers used in inhibition studies (>=50% inhibition) while the CYP1A2-selective inhibitor fluvoxamine (10 muM) decreased norCLZ formation in nine.	Ketoconazole	31-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	166-172	
22266842-7	2012	Furafylline, quinidine, and ketoconazole, selective inhibitors of CYP1A2, CYP2D6, and CYP3A4, respectively, inhibited 5-hydroxylorcaserin (IC(50) = 1.914 muM), 7-hydroxylorcaserin (IC(50) = 0.213 muM), and 1-hydroxylorcaserin formation (IC(50) = 0.281 muM), respectively.	Ketoconazole	28-40	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	66-72	
23001793-5	2013	Ketoconazole (inhibitor of CYP3A4/5) inhibited metabolism of (-)-THP or (+)-THP at same degree, whereas the inhibition of fluvoxamine (inhibitor of CYP1A2) on metabolism of (+)-THP was greater than that of (-)-THP; moreover, the metabolic rate of (+)-THP was 5.3-fold of (-)-THP in recombinant human CYP1A2.	Ketoconazole	0-12	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	300-306	
23434495-9	2013	Both quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) showed 60-100% inhibition of M1-M4 and M6 formations in HLMs, while M5 formation was mainly inhibited by alpha-naphthoflavone (CYP1A2 inhibitor, 70-80%) and quercetin (90%).	Ketoconazole	38-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	197-203	
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Ketoconazole	114-126	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	176-182	
22022918-6	2012	This reaction was inhibited significantly by ketoconazole, a CYP3A inhibitor, and azamulin, a mechanism-based inhibitor of CYP3A, while no substantial effect was observed using selective inhibitors for eight other P450s (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1).	Ketoconazole	45-57	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	221-227	
18950609-12	2009	Results with the isoform-selective inhibitors suggest that the isoforms inhibited by ketoconazole (mainly CYP3A4) and diethyldithiocarbamate (mainly CYP2A6, and CYP2E1), but not the isoforms inhibited by furafylline (mainly CYP1A2), sulfaphenazole (mainly CYP2C9) and quinidine (mainly CYP2D6) are involved in the metabolic activation of AFB1.	Ketoconazole	85-97	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	224-230	
18819885-1	2008	OBJECTIVE: To observe the effect of ketoconazole on the activity of cytochrome P450 (CYP) 1A2 and 3A4 in hepatic microsomes of healthy adults.	Ketoconazole	36-48	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	68-93	
18819885-9	2008	Significant differences were found between the ketoconazole groups and the control group in both the quantity of acetaminophen and the relative activity of CYP1A2 (P<0.05).	Ketoconazole	47-59	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	156-162	
17542019-4	2007	Furafylline, sulfaphenazole, tranylcypromine, quinidine, and ketoconazole were identified as positive control inhibitors for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, respectively.	Ketoconazole	61-73	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	125-131	
19843060-5	2009	RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions.	Ketoconazole	46-58	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	28-34	
18819885-10	2008	Ketoconazole at low doses reduced CYP1A2 activity and but increased the activities at high doses (P<0.05).	Ketoconazole	0-12	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	34-40	
15618748-10	2003	Ketoconazole inhibited all tested drug oxidations, however, its inhibitory effect on CYP1A2-dependent activities was very weak (50% inhibition at 120 microM).	Ketoconazole	0-12	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	85-91